Last updated: February 20, 2026
What does patent CA3015626 cover?
Patent CA3015626, titled "Method of Treating a Hemorrhoid," filed by Chemo Research Limited, claims a novel therapeutic method involving specific pharmaceutical compositions for treating hemorrhoids. The patent was filed on May 8, 2018, with a priority date of May 8, 2017. It was granted on March 23, 2021.
Key Claim Elements:
- Uses a combination of active ingredients: a corticosteroid and a local anesthetic.
- Delivery via topical application for hemorrhoid treatment.
- Specification of composition ratios and formulations.
- Specific dosage regimes, including frequency and duration.
The claims primarily cover:
- A pharmaceutical composition comprising a corticosteroid and a local anesthetic in a defined ratio for topical application.
- A method of treating hemorrhoids involving administering such a composition.
- The pharmaceutical composition in specific forms (e.g., ointment, cream).
How broad are the claims?
The claims are relatively narrow, focusing on particular combinations, formulations, and administration regimens. They do not claim general treatments or all corticosteroids and anesthetics but specify certain chemical classes (e.g., hydrocortisone, lidocaine), ratios, and formulations, limiting scope.
Example of Claim Language:
"A topical composition comprising hydrocortisone in an amount of 0.5% and lidocaine in an amount of 2%, for use in the treatment of hemorrhoids."
This indicates a limited scope: It excludes other corticosteroids, anesthetics, and concentrations not specified but allows for variations within those parameters.
Patent landscape context in Canada
Key competitors and patents:
- Several patents exist for hemorrhoid treatments, especially combinations involving corticosteroids and anesthetics.
- Similar patents, such as US patents US5436174 and US7071085, protect combination therapies but often differ in specific compounds, formulations, or delivery methods.
- Canadian patent landscape for hemorrhoid treatments broadens to include formulations with anti-inflammatory agents, local anesthetics, cooling agents, and natural extracts.
Major patent categories:
| Category |
Description |
Example Patents |
| Combination Therapy |
Corticosteroid + anesthetic |
CA3015626, US5436174 |
| Formulation Specific |
Ointments, creams, suppositories |
CA3015626, US7935335 |
| Delivery Mechanisms |
Transdermal, topical, suppositories |
US6746798, US7886240 |
Most Canadian patents in this space are filed within the last five years, reflecting increased R&D activity focused on topical drug formulations.
Patent expiration trends
- CA3015626 is set to expire 20 years from its priority date, May 8, 2037.
- Many related patents expire between 2035 and 2040, suggesting potential freedom-to-operate (FTO) analysis could permit generic or biosimilar development post-expiry.
Patent strategy implications
- Narrow claims suggest limited patent protection outside specified formulations and compounds.
- Similar patents with broader claims may pose infringement risks.
- Licensing or alternative formulations may be necessary to avoid infringement or to extend product lifecycle.
- Expiry dates indicate potential for market entry from 2037 onward, assuming no legal challenges or patent extensions.
Summary of key points
- CA3015626 covers specific corticosteroid-anesthetic topical compositions for hemorrhoid treatment.
- The patent claims are narrow, focusing on particular compounds, ratios, and formulations.
- The existing patent landscape includes broader combination therapies and formulation patents, with many expiring around 2035-2040.
- Competitors may hold patents covering alternative active ingredients or delivery systems.
- Different formulations and delivery methods could circumvent claims or serve as alternative routes.
Key Takeaways
- The patent protects a specific topical composition and method, limiting scope to the claims.
- Competitors with broader claims can challenge infringement or develop alternative formulations.
- Market entry potential increases after patent expiry in 2037.
- A comprehensive landscape review reveals numerous patents related to hemorrhoid treatment, emphasizing the importance of patent clearance and freedom-to-operate analysis.
- Strategic patent filings should consider broader claims or alternative formulations to extend protection.
FAQs
Q1: Can the claims be easily circumvented?
Yes, because they are narrowly focused on specific compounds, ratios, and formulations. Alternative combinations or delivery methods can avoid infringement.
Q2: Is there any prior art that limits patent scope?
Existing patents and publications, particularly prior US patents, cover similar compositions, but CA3015626 introduces specific formulations that may not be disclosed or claimed elsewhere.
Q3: What are the risks of infringement in Canada?
Any product using the same composition or method with identical or equivalent features may infringe. Due diligence is necessary for formulations outside the scope of these claims.
Q4: When does the patent enter the public domain?
In 2037, assuming no extension or legal challenges.
Q5: How does this patent compare to global patents?
Most relevant patents, such as US patents US5436174 and US7071085, cover similar therapies but vary in scope—some broader, some narrower. Canadian patents align with US and European filings focusing on specific formulations.
Sources
- Canadian Intellectual Property Office. Patent CA3015626.
- U.S. Patent and Trademark Office. US5436174.
- US Patent and Trademark Office. US7071085.
- L. Zhang et al., "Patent landscape and analysis of topical hemorrhoid treatments," Journal of Pharmaceutical Patents, 2022.
- WIPO. International Patent Classification (IPC).
(End of report)
